Skip to main content

Advertisement

Long term immune reconstitution after immunoablation and autologous CD34 cell therapy in autoimmune diseases

Article metrics

  • 1022 Accesses

Introduction

Immunoablation in combination with autologous stem cell transplantation (ASCT) is used as a therapy for severe autoimmune diseases. We have analysed reconstitution of the immune system in patients treated with ASCT.

Results

During a follow-up period of up to 42 months after ASCT, one polychondritis and two systemic lupus erythematosus (SLE) patients in clinical remission were analysed for reappearance of naive, activated and memory B and T lymphocytes, for reactivity against pathogens and autoantigens, and for presence of autoantibodies. Titers of disease-specific autoantibodies decreased after ASCT with the half-life of secreted antibodies, and did not reappear. NaiveT and naive Bcells reappeared and reached normal levels within one year after ASCT. T cells activated and expanded by pathogens were easily detectable, but not T cells reacting to any of an array of autoantigens tested, in a cytometric cytokine provocation test. A third SLE patient suffered from a relapse of disease after being free of any clinical and serological symptoms for 17 months. In this patient, autoantibodies with old (anti-dsDNA antibodies) and new specificities (anti-Sm and anti-U1RNP antibodies) appeared upon relapse. A sudden decrease of peripheral naive and increase of peripheral memory B and Th cells preceeded the relapse.

Conclusion

ASCT for autoimmune diseases can result in longlasting remissions. According to frequencies and phenotypes of naive lymphocytes, the reconstituted immune system resembles a 'juvenile' immune system. Our results reveal that autoreactive and plasma cells do not survive the therapy but protective immune memory has to be re-established.

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thiel, A., Thiel, A., Alexander, T. et al. Long term immune reconstitution after immunoablation and autologous CD34 cell therapy in autoimmune diseases. Arthritis Res Ther 4, 107 (2002) doi:10.1186/ar442

Download citation

Keywords

  • Systemic Lupus Erythematosus
  • Autoimmune Disease
  • Systemic Lupus Erythematosus Patient
  • Cell Therapy
  • CD34 Cell